Semaglutide vs. tirzepatide for weight loss: what the head-to-head trial showed

Semaglutide (the molecule in Wegovy and Ozempic) and tirzepatide (Zepbound and Mounjaro) are the two most effective weight-loss medications widely available. They are often discussed as if interchangeable, but they work differently — and they have now been compared head-to-head in a randomized trial.

The mechanisms are not the same

Semaglutide is a GLP-1 receptor agonist: it activates one gut-hormone receptor involved in appetite and satiety. Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP receptor. That second pathway is why tirzepatide is sometimes called a 'twincretin,' and it is the leading explanation for why it tends to produce greater weight loss in trials.

SURMOUNT-5: the direct comparison

SURMOUNT-5 randomized 751 adults to tirzepatide or semaglutide over 72 weeks. Tirzepatide produced a mean weight loss of 20.2%, versus 13.7% for semaglutide (p<0.001). About 31.6% of the tirzepatide group achieved at least 25% body-weight loss, compared with 16.1% on semaglutide. Notably, gastrointestinal-related discontinuations were lower with tirzepatide (2.7% vs 5.6%). These are clinical-trial results for the brand-name molecules.

Does that make tirzepatide always the better choice?

Not necessarily. Averages from a trial do not predict any individual's result. Some people tolerate one medication better than the other, cost and availability differ, and semaglutide has a longer track record in some settings. Tirzepatide showed the larger average weight loss and, in this trial, fewer GI-related discontinuations — but the right medication is the one a provider determines fits your history, your goals, and how your body responds.

• Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both GLP-1 and GIP
• SURMOUNT-5 (72 weeks): tirzepatide −20.2% vs semaglutide −13.7% mean weight loss
• ≥25% weight loss: 31.6% (tirzepatide) vs 16.1% (semaglutide)
• GI-related discontinuations were lower with tirzepatide in this trial
• Individual response, tolerability, cost, and availability still matter — this is a clinical decision